← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › PROGESTOGENS AND ESTROGENS IN COMBINATION › Progestogens and estrogens, sequential preparations
nomegestrol and estrogen
G03FB12
Forms & Strengths
- Oral tablets: Nomegestrol acetate 2.5 mg / Estradiol 1.5 mg
Adult Dosing
- 1 tablet daily taken orally for 28 consecutive days per cycle, without a break between packs
- Taken continuously, starting on day 1 of menstrual bleeding or as directed
Pediatric Dosing
- Not indicated for premenarchal pediatric use
- Safety and efficacy established only after menarche
Indications
- Hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women (at least 12 months since last menses)
- Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of other approved medications
Mechanism of Action
- Estradiol replaces endogenous estrogen loss, relieving menopausal vasomotor symptoms and preventing bone resorption
- Nomegestrol acetate is a potent progestogen that opposes estrogenic endometrial proliferation, reducing the risk of endometrial hyperplasia and carcinoma
Contraindications
- Known or suspected breast cancer
- Known or suspected estrogen- or progestogen-dependent malignant tumors
- Undiagnosed genital bleeding
- Active or previous venous thromboembolism (deep vein thrombosis, pulmonary embolism)
- Active or recent arterial thromboembolic disease (angina, myocardial infarction)
- Known hepatic impairment or active liver disease until liver function tests have returned to normal
- Known hypersensitivity to the active substances or any excipients
Adverse Reactions
- Common: Headaches, breast pain/tenderness, irregular uterine bleeding, weight fluctuations
- Uncommon: Mood alterations, libido changes, dizziness, nausea, abdominal pain, acne, alopecia, peripheral edema
- Rare: Venous and arterial thromboembolism, gallbladder disease, hepatocellular tumors
Drug Interactions
- Hepatic enzyme inducers (e.g., barbiturates, carbamazepine, carbamazepine, phenytoin, rifampicin, St. John's wort) decrease plasma concentrations of estradiol and nomegestrol
- Inhibitors of CYP3A4 (e.g., ketoconazole, erythromycin) may increase plasma concentrations of estradiol
- Concomitant use with HCV combination therapies containing ombitasvir/paritaprevir/ritonavir and dasabuvir may increase the risk of ALT elevations
Curated Content: Needs Vetting Before Put to Clinical Use